Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma
Kate Lynn J. Bill(The Ohio State University Wexner Medical Center), James L. Chen(Mayo Clinic)
Cited by 42
Related Papers
Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression
|Cancer Research|2017|199
Differences in Mechanisms of Failure, Intraoperative Findings, and Surgical Characteristics Between Single- and Multiple-Revision ACL Reconstructions
|The American Journal of Sports Medicine|2013|157
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
|Clinical Cancer Research|2015|106